OncoMatch/Clinical Trials/NCT06611137
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
Is NCT06611137 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies SBRT+Toripalimab Plus Docetaxel and Cisplatin for laryngeal cancer.
Treatment: SBRT+Toripalimab Plus Docetaxel and Cisplatin — This trial aims to evaluate the safety and efficiency of SBRT followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage T3-4N0-3M0, T2-4N0-3M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
normal functions to tolerate chemotherapy, immunotherapy and radiotherapy
Kidney function
normal functions to tolerate chemotherapy, immunotherapy and radiotherapy
Liver function
normal functions to tolerate chemotherapy, immunotherapy and radiotherapy
Cardiac function
normal functions to tolerate chemotherapy, immunotherapy and radiotherapy
normal functions to tolerate chemotherapy, immunotherapy and radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06611137 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage T3-4N0-3M0 or T2-4N0-3M0 is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages